Veterinary Vaccines Market

Veterinary Vaccines Market by Type (Porcine, Poultry, Livestock, Companion Animals), Technology (Live Attenuated, Inactivated, Toxoid), Route of Administration (Injection, Intranasal), Distribution Channel (Hospitals, Clinics) - Global Forecast to 2027

Report Code: PH 3475 Apr, 2023, by marketsandmarkets.com

The global veterinary vaccines market in terms of revenue was estimated to be worth $8.1 billion in 2022 and is poised to reach $10.8 billion by 2027, growing at a CAGR of 5.9% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Growth in this market can primarily be attributed to the growing companion animal population and initiatives by various government agencies and animal associations. A surge in the overall companion animal population and adoption rate has been witnessed on a global scale. According to several studies, having a companion animal is associated with positive health benefits, such as reduced cardiac arrhythmias, normalization of blood pressure, decreased anxiety, greater psychological stability, and improved well-being. The increasing pet population is expected to drive the demand for pet care products and services, which, in turn, will support the growth of dependent industries such as veterinary vaccines.

Attractive Opportunities in Veterinary Vaccines Market

Veterinary Vaccines Market

To know about the assumptions considered for the study, Request for Free Sample Report

Veterinary Vaccines Market

Global Veterinary Vaccines Market Dynamics

Driver: Rising demand for animal-derived food products

The global demand for animal-derived food products, including beef, veal, buffalo meat, mutton, lamb and goat meat, pork, poultry meat, milk and dairy products, and eggs, is increasing. Livestock products account for 17% of kilocalorie consumption and 33% of protein consumption globally; however, this figure varies across developed and developing countries. The overall livestock sector is expected to witness significant growth due to the high consumption of animal-derived food products. An FAO (Food and Agriculture Organization of the United Nations) survey on mapping the supply and demand for animal-sourced food estimates that Asian countries will register the highest growth in the demand for livestock products such as beef, milk, mutton, pork, and poultry products (chicken and eggs). According to the Guardian and Bureau of Investigative Journalism, the number of industrial-sized pig and poultry units in the UK has risen by 7% from 1,669 in 2017 to 1,786 in 2020.

Restraint: High storage cost of veterinary vaccines

Effective storage is a key issue faced by manufacturers across the supply chain for veterinary vaccines. Vaccines are mainly stored at low temperatures using deep freezing, and this low temperature should be maintained during storage and transportation until the vaccine is administered to animals. A small error in the storage of vaccines can cost thousands of dollars in vaccine wastage and revaccination programs.

Cold storage-related spending on vaccines amounts to about 80% of their total cost. For effective storage, vaccine manufacturers and distributors widely use various vaccine storage equipment and monitoring devices such as refrigerators, thermometers, and cold chain monitors. A typical single vaccine storage refrigerator costs between USD 2,000–50,000, depending on the size of the unit and the number of vaccines being stored. To maintain the recommended temperature, vaccine storage equipment needs to be selected carefully, maintained regularly (including professionally serviced), and monitored consistently. Consequently, this process generates significant costs for vaccine manufacturers.

Opportunity: Technology Advancements

Veterinary vaccine technology has evolved significantly over the past decade. This is mainly due to the constant emergence of new diseases or the re-emergence of mutated diseases. Conventional live and inactivated vaccines are sometimes exposed to risks of mutation and have a short shelf life. Similarly, the challenge of strain/region specificity makes conventional vaccines ineffective. To combat these limitations, technologically advanced recombinant and DNA vaccines are being introduced in the market.

The introduction of new vaccines is expected to offer lucrative growth opportunities to animal vaccine manufacturers. These vaccines induce a wider range of immune responses; are easy to produce, store, and transport; can be rapidly developed to combat emerging diseases; and are highly stable as opposed to other vaccine types. DNA vaccines are capable of inducing potent cellular and humoral immune responses and display higher stability at a wider range of temperatures, which also reduces the cost incurred in maintaining the recommended temperature. After successful preclinical tests for H1N1 influenza, players such as VGX Animal Health are now increasing their focus on developing DNA vaccines.

Challenge: Inadequate surveillance and reporting systems

In many cases, despite initiatives to promote the use of vaccines, the overall vaccine coverage is found to be low. This is mainly due to the lack of awareness about vaccination and inadequate surveillance and reporting systems. Even when vaccines are available, a lack of data can complicate decisions about areas where vaccines are needed.

Surveillance and reporting systems are still inadequate for many diseases and in many countries, which is resulting in the late diagnosis and reporting of disease outbreaks. This issue is primarily related to funding, as farmers are often reluctant to pay for diagnostic tests or surveillance and reporting. Investments and funding for improving surveillance and reporting systems are expected to ultimately transfer the benefits to human health by reducing the overall prevalence of zoonotic diseases. However, until such investments are made available, the presence of inadequate surveillance and reporting systems is expected to continue to hinder the large-scale use of vaccines.

Veterinary Vaccines Market Ecosystem

Prominent companies in this market include well-established, financially stable manufacturers of veterinary vaccines. These companies have been operating in the market for several years and possess a diversified product portfolio, state-of-the-art technologies, and strong global sales and marketing networks. Prominent companies in this market include Zoetis, Inc.(US), Merck & Co, Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco Animal Health (US), Virbac (France).

Veterinary Vaccines Market Ecosystem

The companion animal vaccines segment of veterinary vaccines industry is expected to register the highest CAGR during the forecast period

Based on type, the global veterinary vaccines market is segmented into porcine vaccines, poultry vaccines, livestock vaccines, companion animal vaccines, aquaculture vaccines, and other animal vaccines. In 2021, the companion animal vaccines segment is expected to register the highest CAGR during the forecast period. Increasing awareness about vaccination, the rising prevalence of zoonotic diseases in humans, and the growing number of pets and pet owners are fueling the demand for these vaccines.

The bovine vaccines segment of veterinary vaccines industry is estimated to grow at a higher CAGR during the forecast period

Based on diseases, the global veterinary vaccines market is segmented into bovine and small ruminants animals diseases. The bovine vaccines segment is estimated to grow at a higher CAGR during the forecast period. Growth in this segment can be attributed to the increasing demand for meat & milk, growth in the dairy industry, and increasing awareness about the prevention of diseases in livestock.

Injectable vaccines segment of veterinary vaccines industry is expected to grow at the highest CAGR during the forecast period

Based on the route of administration, the global veterinary vaccines market is segmented into injectable vaccines, oral vaccines, and intranasal/spray vaccines. In 2021, injectable vaccines segment is expected to grow at the highest CAGR during the forecast period. This route of administration is preferred over the oral route, as some vaccines are destroyed by the digestive system when swallowed. Subcutaneous injections are administered into fatty tissues, below the skin and above the muscle. These injections are useful, safe, and convenient, especially for delivering small amounts of delicate medication

APAC is estimated to be the fastest-growing region for veterinary vaccines industry

The global veterinary vaccines market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2021, APAC is estimated to be the fastest-growing regional market for veterinary vaccines. The high growth in this market can majorly be attributed to the rising companion animal population and the expansion of key players in the market in several Asia Pacific countries such as India, China, and Thailand. Livestock farming is a major source of income in various countries in the Asia Pacific. This is a major reason for the large livestock population in this region. The demand for animal-based products such as meat and milk is increasing in emerging Asia Pacific markets; owing to this, revenues from livestock products are also increasing. In this scenario, ensuring the health of animals and maintaining their productivity gains added importance, which has increased the adoption of veterinary vaccines in this region.

Veterinary Vaccines Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The global Veterinary Vaccines market is dominated by a few globally established players such as Zoetis, Inc.(US), Merck & Co, Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco Animal Health (US), Virbac (France). Major players adopt growth strategies to expand their geographical presence and garner higher shares in the global market, such as product launches and approvals, expansions, collaborations, and acquisitions.

Scope of the Veterinary Vaccines Industry:

Report Metric

Details

Market size available for years

2020–2027

Base year considered

2021

Forecast period

2022–2027

Forecast units

Value (USD)

Segments covered

By type, disease, technology, route of administration, distribution channel

Geographies covered

North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa

Companies covered

Zoetis, Inc.(US), Merck & Co, Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco Animal Health (US), Virbac (France), Ceva Santé Animale (France), Phibro Animal Health Corporation (US), Hester Biosciences Limited (India), Neogen Corporation (US), HIPRA (Spain), Biogénesis Bagó (Argentina), Tianjin Ringpu Bio-Technology Co Ltd. (China), China Animal Husbandry Group (China), Jinyu Bio-technology (China), Vaxxinova International BV (Netherlands), Endovac Animal Health (US), Brilliant Bio Pharma (India), Aptimmune (US), Indian Immunologicals Ltd. (India), Torigen Pharmaceuticals, Inc. (US), VEROVACCiNES GmbH (Germany), Intas Pharmaceuticals (India), Ourofino Animal Health (Brazil), Biovac (Israel), and Laboratoire LCV (France)

The study categorizes the global veterinary vaccines market to forecast revenue and analyze trends in each of the following submarkets:

By Type

  • Porcine Vaccines
  • Poultry Vaccines
  • Livestock Vaccines
    • Bovine Vaccines
    • Small Ruminant Vaccines
  • Companion Animal Vaccines
    • Canine Vaccines
    • Feline Vaccines
  • Aquaculture Vaccines
  • Other Animal Vaccines

By Disease

  • Porcine Diseases
  • Poultry Diseases
  • Livestock Diseases
    • Bovine Diseases
    • Small Ruminant Diseases
  • Companion Animal Diseases
    • Canine Diseases
    • Feline Diseases
  • Aquaculture Diseases

By Technology

  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Toxoid Vaccines
  • Recombinant Vaccines
  • Other Vaccines

By Route of Administration

  • Injection Vaccines
  • Oral Vaccines
  • Intranasal/Spray Vaccines

By Distribution Channel

  • Veterinary Hospitals
  • Veterinary Clinics
  • Retail Pharmacies

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

Recent Developments of Veterinary Vaccines Industry

  • In September 2022, Zoetis acquired Jurox, a privately held animal health company that develops, manufactures, and markets a wide range of veterinary medicines for treating livestock and companion animals.
  • In June 2022, Boehringer Ingelheim and CarthroniX partnered to pursue small molecule therapeutics in canine oncology.
  • In July 2021, Elanco acquired KindredBio, a biopharmaceutical company focused on developing novel pet therapeutics.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 25)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
          TABLE 1 STANDARD CURRENCY CONVERSION RATES
    1.5 LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
    1.8 RECESSION IMPACT 
 
2 RESEARCH METHODOLOGY (Page No. - 31)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 2 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                                FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS, BY COMPANY TYPE, DESIGNATION, AND REGION
                                FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: DEMAND-SIDE PARTICIPANTS, BY END USER, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 6 GLOBAL VETERINARY VACCINES MARKET RESEARCH: SUPPLY-SIDE MARKET SIZE ESTIMATION
          FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: MERCK & CO., IN.
          FIGURE 8 ANIMAL VACCINES MARKET: SUPPLY-SIDE ANALYSIS OF LEADING COMPANIES (2021)
          FIGURE 9 ANIMAL VACCINES MARKET: CAGR PROJECTION FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022–2027)
          FIGURE 10 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS
          FIGURE 11 TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 12 MARKET DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ANALYSIS 
    2.5 STUDY ASSUMPTIONS 
    2.6 RISK ASSESSMENT 
          TABLE 2 MARKET: RISK ASSESSMENT ANALYSIS
    2.7 LIMITATIONS 
           2.7.1 METHODOLOGY-RELATED LIMITATIONS
           2.7.2 SCOPE-RELATED LIMITATIONS
    2.8 MARKET: RECESSION IMPACT 
 
3 EXECUTIVE SUMMARY (Page No. - 45)
    FIGURE 13 GLOBAL VETERINARY VACCINES MARKET SIZE, BY TYPE, 2022 VS. 2027 (USD MILLION)
    FIGURE 14 ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    FIGURE 15 VETERINARY VACCINES MARKET FORECAST, BY DISEASE, 2022 VS. 2027 (USD MILLION)
    FIGURE 16 ANIMAL VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022 VS. 2027 (USD MILLION)
    FIGURE 17 MARKET, BY DISTRIBUTION CHANNEL, 2022 VS. 2027 (USD MILLION)
    FIGURE 18 VETERINARY VACCINES MARKET GROWTH: GEOGRAPHICAL SNAPSHOT
 
4 PREMIUM INSIGHTS (Page No. - 49)
    4.1 GLOBAL VETERINARY VACCINES MARKET OVERVIEW 
          FIGURE 19 RISING GROWTH IN COMPANION ANIMAL POPULATION TO DRIVE MARKET
    4.2 ASIA PACIFIC: MARKET, BY TECHNOLOGY (2021) 
          FIGURE 20 LIVE ATTENUATED VACCINES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2021
    4.3 ANIMAL VACCINES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 21 CHINA TO WITNESS HIGHEST CAGR DURING FORECAST PERIOD
    4.4 ANIMAL VACCINES MARKET, BY REGION 
          FIGURE 22 ASIA PACIFIC REGION TO DOMINATE MARKET DURING FORECAST PERIOD
    4.5 ANIMAL VACCINES MARKET: DEVELOPED VS. EMERGING ECONOMIES 
          FIGURE 23 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 53)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 24 GLOBAL VETERINARY VACCINES MARKET ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Growth in companion animal population
                                TABLE 3 EUROPEAN PET POPULATION, BY ANIMAL, 2016–2022 (MILLION)
                    5.2.1.2 Rising incidence of zoonotic diseases
                                TABLE 4 ANIMAL DISEASE OUTBREAKS IN ASIA PACIFIC COUNTRIES (2009–2019)
                    5.2.1.3 Initiatives by various government agencies and animal associations
                    5.2.1.4 Rising demand for animal-derived food products
                                TABLE 5 PAST AND PROJECTED TRENDS IN CONSUMPTION OF MEAT AND MILK (DEVELOPED VS. EMERGING MARKETS)
                                TABLE 6 ASIA: COUNTRY-LEVEL CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS)
                                TABLE 7 ASIA: COUNTRY-LEVEL PRODUCTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS)
                    5.2.1.5 Growing demand for pet insurance and rising animal health expenditure
                                TABLE 8 US: AVERAGE PREMIUMS PAID (2019–2021)
                                FIGURE 25 CANADA: AVERAGE ANNUAL PREMIUMS, 2017–2021
                                FIGURE 26 US: PET INDUSTRY EXPENDITURE, 2010–2021
                                TABLE 9 US: BREAKDOWN OF PET INDUSTRY EXPENDITURE, 2020 VS. 2021 (USD BILLION)
                                TABLE 10 NORTH AMERICA: PET HEALTH INSURANCE MARKET, 2012–2021 (USD MILLION)
           5.2.2 RESTRAINTS
                    5.2.2.1 High storage cost of vaccines
                    5.2.2.2 Rising pet care costs
                                FIGURE 27 US: BASIC ANNUAL EXPENSES FOR DOGS AND CATS, 2021
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Technological advancements
                    5.2.3.2 Untapped emerging markets
           5.2.4 CHALLENGES
                    5.2.4.1 Inadequate surveillance and reporting systems
                    5.2.4.2 Lack of animal healthcare awareness in emerging countries
    5.3 INDUSTRY TRENDS 
           5.3.1 GROWING SCALE OF VETERINARY BUSINESSES
    5.4 REGULATORY ANALYSIS 
           5.4.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 11 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           5.4.2 US
           5.4.3 EUROPE
           5.4.4 REST OF THE WORLD
    5.5 VALUE CHAIN ANALYSIS 
          FIGURE 28 ANIMAL VACCINES MARKET: VALUE CHAIN ANALYSIS
    5.6 SUPPLY CHAIN ANALYSIS 
          FIGURE 29 VETERINARY VACCINES MARKET RESEARCH: SUPPLY CHAIN ANALYSIS
    5.7 ECOSYSTEM ANALYSIS 
          FIGURE 30 MARKET: ECOSYSTEM ANALYSIS
    5.8 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 12 PORTER’S FIVE FORCES ANALYSIS
           5.8.1 THREAT OF NEW ENTRANTS
           5.8.2 THREAT OF SUBSTITUTES
           5.8.3 BARGAINING POWER OF SUPPLIERS
           5.8.4 BARGAINING POWER OF BUYERS
           5.8.5 INTENSITY OF COMPETITIVE RIVALRY
    5.9 PATENT ANALYSIS 
           5.9.1 PATENT PUBLICATION TRENDS FOR VETERINARY VACCINES
                    FIGURE 31 PATENT PUBLICATION TRENDS (JANUARY 2013–MARCH 2023)
           5.9.2 JURISDICTION AND TOP APPLICANT ANALYSIS
                    FIGURE 32 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR VETERINARY VACCINES PATENTS (JANUARY 2013–MARCH 2023)
                    FIGURE 33 TOP APPLICANT COUNTRIES/REGIONS FOR VETERINARY VACCINES PATENTS (JANUARY 2013–MARCH 2023)
    5.10 TECHNOLOGY ANALYSIS 
    5.11 INDICATIVE PRICING MODEL ANALYSIS 
           TABLE 13 AVERAGE SELLING PRICE OF VETERINARY VACCINES
           5.11.1 AVERAGE SELLING PRICE TRENDS
    5.12 KEY CONFERENCES AND EVENTS (2023–2025) 
           TABLE 14 ANIMAL VACCINES MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
    5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR VETERINARY VACCINES
                     TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR VETERINARY VACCINES
           5.13.2 BUYING CRITERIA
                     FIGURE 35 KEY BUYING CRITERIA FOR VETERINARY VACCINES
                     TABLE 16 KEY BUYING CRITERIA FOR VETERINARY VACCINES
 
6 GLOBAL VETERINARY VACCINES MARKET GROWTH, BY TYPE (Page No. - 81)
    6.1 INTRODUCTION 
          TABLE 17 ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
    6.2 LIVESTOCK VACCINES 
          TABLE 18 LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 19 LIVESTOCK VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           6.2.1 BOVINE VACCINES
                    6.2.1.1 Bovine vaccines segment to dominate market
                                TABLE 20 BOVINE VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           6.2.2 SMALL RUMINANT VACCINES
                    6.2.2.1 Small ruminant vaccines segment to register lower growth in livestock vaccines market
                                TABLE 21 SMALL RUMINANT VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.3 PORCINE VACCINES 
           6.3.1 SECOND-LARGEST MARKET DURING FORECAST PERIOD
                    TABLE 22 PORCINE VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.4 POULTRY VACCINES 
           6.4.1 INCREASED PRODUCTION AND REARING OF POULTRY TO DRIVE MARKET GROWTH
                    TABLE 23 POULTRY VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.5 COMPANION ANIMAL VACCINES 
          TABLE 24 COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 25 COMPANION ANIMAL VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           6.5.1 CANINE VACCINES
                    6.5.1.1 Canine vaccines segment to dominate companion animal vaccines market during forecast period
                                TABLE 26 CANINE VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           6.5.2 FELINE VACCINES
                    6.5.2.1 Rising prevalence of zoonotic diseases to drive demand for feline vaccines
                                TABLE 27 FELINE VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.6 AQUACULTURE VACCINES 
           6.6.1 VACCINATION PLAYS CRUCIAL ROLE IN COMMERCIAL FISH FARMING
                    TABLE 28 AQUACULTURE VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.7 OTHER ANIMAL VACCINES 
          TABLE 29 OTHER COMPANION ANIMAL VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
 
7 GLOBAL VETERINARY VACCINES MARKET GROWTH, BY DISEASE (Page No. - 93)
    7.1 INTRODUCTION 
          TABLE 30 ANIMAL VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION)
    7.2 PORCINE DISEASES 
           7.2.1 PORCINE CIRCOVIRUS II TO ACCOUNT FOR LARGEST SHARE OF PORCINE VACCINES MARKET
                    TABLE 31 PORCINE VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                    TABLE 32 PORCINE DISEASES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    7.3 POULTRY DISEASES 
           7.3.1 INFECTIOUS BRONCHITIS SEGMENT TO ACCOUNT FOR LARGEST SHARE OF POULTRY VACCINES MARKET
                    TABLE 33 POULTRY VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                    TABLE 34 POULTRY DISEASES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    7.4 LIVESTOCK DISEASES 
          TABLE 35 LIVESTOCK VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION)
          TABLE 36 LIVESTOCK DISEASES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           7.4.1 BOVINE DISEASES
                    7.4.1.1 Foot-and-mouth disease segment to account for largest share of bovine vaccines market
                                TABLE 37 BOVINE VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                                TABLE 38 BOVINE DISEASES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           7.4.2 SMALL RUMINANT DISEASES
                    7.4.2.1 Clostridial disease segment to account for largest share of small ruminant vaccines market
                                TABLE 39 SMALL RUMINANT VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                                TABLE 40 SMALL RUMINANT DISEASES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    7.5 COMPANION ANIMAL DISEASES 
          TABLE 41 COMPANION ANIMAL VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION)
          TABLE 42 COMPANION ANIMAL DISEASES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           7.5.1 CANINE DISEASES
                    7.5.1.1 Canine rabies segment to account for largest share of canine vaccines market
                                TABLE 43 CANINE VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                                TABLE 44 CANINE DISEASES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           7.5.2 FELINE DISEASES
                    7.5.2.1 Feline viral rhinotracheitis segment to grow at highest CAGR during forecast period
                                TABLE 45 FELINE VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                                TABLE 46 FELINE DISEASES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    7.6 AQUACULTURE DISEASES 
           7.6.1 VACCINES IN AQUACULTURE MAJORLY DEVELOPED FOR SALMONIDS, CATFISH, AND SHRIMP
                    TABLE 47 AQUACULTURE DISEASES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
 
8 GLOBAL VETERINARY VACCINES MARKET GROWTH, BY TECHNOLOGY (Page No. - 107)
    8.1 INTRODUCTION 
          TABLE 48 ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
    8.2 LIVE ATTENUATED VACCINES 
           8.2.1 LIVE ATTENUATED VACCINES SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
                    TABLE 49 LIVE ATTENUATED VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    8.3 INACTIVATED VACCINES 
           8.3.1 RISING NEED TO DEVELOP ARTIFICIAL IMMUNITY AGAINST DISEASES FROM NON-LIVING PATHOGENS TO DRIVE GROWTH
                    TABLE 50 INACTIVATED VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    8.4 TOXOID VACCINES 
           8.4.1 TOXOID VACCINES USED WHEN BACTERIAL TOXINS CAUSE ILLNESS
                    TABLE 51 TOXOID VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    8.5 RECOMBINANT VACCINES 
           8.5.1 ADVANTAGES ASSOCIATED WITH RECOMBINANT VACCINES TO DRIVE DEMAND
                    TABLE 52 RECOMBINANT VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    8.6 OTHER VACCINES 
          TABLE 53 OTHER VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
 
9 GLOBAL VETERINARY VACCINES MARKET GROWTH, BY ROUTE OF ADMINISTRATION (Page No. - 114)
    9.1 INTRODUCTION 
          TABLE 54 ROUTES OF ADMINISTRATION OF MAJOR VETERINARY VACCINES
          TABLE 55 ANIMAL VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
    9.2 INJECTABLE VACCINES 
           9.2.1 INJECTABLE VACCINES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
                    TABLE 56 INJECTABLE VETERINARY VACCINE MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    9.3 ORAL VACCINES 
           9.3.1 ORAL VACCINES MAKE IMMUNIZATION EASIER
                    TABLE 57 ORAL VETERINARY VACCINE MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    9.4 INTRANASAL/SPRAY VACCINES 
           9.4.1 LOW COST OF INTRANASAL/SPRAY VACCINES TO SUPPORT MARKET GROWTH
                    TABLE 58 INTRANASAL/SPRAY VETERINARY VACCINE MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
 
10 GLOBAL VETERINARY VACCINES MARKET ANALYSIS, BY DISTRIBUTION CHANNEL (Page No. - 121)
     10.1 INTRODUCTION 
             TABLE 59 VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
     10.2 VETERINARY HOSPITALS 
             10.2.1 VETERINARY HOSPITALS FORM LARGEST AND FASTEST-GROWING END-USER SEGMENT IN MARKET
                        TABLE 60 US: VETERINARY VISIT EXPENSES FOR CATS AND DOGS
                        TABLE 61 MARKET FOR VETERINARY HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION)
     10.3 VETERINARY CLINICS 
             10.3.1 INCREASING NUMBER OF PRIVATE CLINICAL PRACTICES TO SUPPORT MARKET GROWTH
                        TABLE 62 NUMBER OF PRIVATE CLINICAL PRACTICES, BY COUNTRY, 2019 VS. 2021
                        TABLE 63 MARKET FOR VETERINARY CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)
     10.4 RETAIL PHARMACIES 
             10.4.1 EASY ACCESSIBILITY TO PHARMACEUTICALS TO SUPPORT MARKET GROWTH
                        TABLE 64 MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2020–2027 (USD MILLION)
 
11 GLOBAL VETERINARY VACCINES MARKET ANALYSIS, BY REGION (Page No. - 127)
     11.1 INTRODUCTION 
             TABLE 65 ANIMAL VACCINES MARKET, BY REGION, 2020–2027 (USD MILLION)
     11.2 ASIA PACIFIC 
             11.2.1 ASIA PACIFIC: RECESSION IMPACT
                        FIGURE 36 ASIA PACIFIC: VETERINARY VACCINES MARKET SNAPSHOT
                        TABLE 66 ASIA PACIFIC: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                        TABLE 67 ASIA PACIFIC: MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 68 ASIA PACIFIC: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 69 ASIA PACIFIC: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 70 ASIA PACIFIC: ANIMAL VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                        TABLE 71 ASIA PACIFIC: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 72 ASIA PACIFIC: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 73 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 74 ASIA PACIFIC: MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                        TABLE 75 ASIA PACIFIC: ANIMAL VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
             11.2.2 CHINA
                        11.2.2.1 China to dominate Asia Pacific veterinary vaccines market
                                      TABLE 76 CHINA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 77 CHINA: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 78 CHINA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 79 CHINA: MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                                      TABLE 80 CHINA: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 81 CHINA: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 82 CHINA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 83 CHINA: MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                                      TABLE 84 CHINA: ANIMAL VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
             11.2.3 JAPAN
                        11.2.3.1 Increasing expenditure on pet healthcare to drive market growth
                                      TABLE 85 PRODUCTION AND CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS IN JAPAN (2000 VS. 2030) (THOUSAND METRIC TONS)
                                      TABLE 86 JAPAN: VETERINARY VACCINES MARKET FORECAST, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 87 JAPAN: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 88 JAPAN: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 89 JAPAN: ANIMAL VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                                      TABLE 90 JAPAN: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 91 JAPAN: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 92 JAPAN: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 93 JAPAN: MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                                      TABLE 94 JAPAN: VETERINARY VACCINES MARKET ANALYSIS, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
             11.2.4 INDIA
                        11.2.4.1 Dearth of veterinarians to restrain market growth
                                      TABLE 95 PRODUCTION AND CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS IN INDIA (2000 VS. 2030) (THOUSAND METRIC TONS)
                                      TABLE 96 INDIA: VETERINARY VACCINES MARKET PREDICTION, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 97 INDIA: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 98 INDIA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 99 INDIA: MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                                      TABLE 100 INDIA: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 101 INDIA: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 102 INDIA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 103 INDIA: MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                                      TABLE 104 INDIA: ANIMAL VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
             11.2.5 AUSTRALIA
                        11.2.5.1 Increase in pet ownership to support market growth
                                      TABLE 105 AUSTRALIA: VETERINARY VACCINES MARKET RESEARCH, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 106 AUSTRALIA: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 107 AUSTRALIA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 108 AUSTRALIA: ANIMAL VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                                      TABLE 109 AUSTRALIA: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 110 AUSTRALIA: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 111 AUSTRALIA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 112 AUSTRALIA: MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                                      TABLE 113 AUSTRALIA: ANIMAL VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
             11.2.6 SOUTH KOREA
                        11.2.6.1 Growing companion animal population to drive market growth
                                      TABLE 114 SOUTH KOREA: VETERINARY VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 115 SOUTH KOREA: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 116 SOUTH KOREA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 117 SOUTH KOREA: MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                                      TABLE 118 SOUTH KOREA: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 119 SOUTH KOREA: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 120 SOUTH KOREA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 121 SOUTH KOREA: MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                                      TABLE 122 SOUTH KOREA: VETERINARY VACCINES MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
             11.2.7 THAILAND
                        11.2.7.1 Growth of pork and poultry industry to drive market
                                      TABLE 123 THAILAND: VETERINARY VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 124 THAILAND: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 125 THAILAND: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 126 THAILAND: ANIMAL VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                                      TABLE 127 THAILAND: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 128 THAILAND: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 129 THAILAND: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 130 THAILAND: MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                                      TABLE 131 THAILAND: ANIMAL VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
             11.2.8 REST OF ASIA PACIFIC
                        TABLE 132 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET SIZE, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 133 REST OF ASIA PACIFIC: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 134 REST OF ASIA PACIFIC: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 135 REST OF ASIA PACIFIC: MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                        TABLE 136 REST OF ASIA PACIFIC: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 137 REST OF ASIA PACIFIC: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 138 REST OF ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 139 REST OF ASIA PACIFIC: MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                        TABLE 140 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET PREDICTION, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
     11.3 NORTH AMERICA 
            FIGURE 37 EXPECTED GROWTH IN NUMBER OF VETERINARIANS IN NORTH AMERICA
             11.3.1 NORTH AMERICA: RECESSION IMPACT
                        FIGURE 38 NORTH AMERICA: VETERINARY VACCINES MARKET SNAPSHOT
                        TABLE 141 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                        TABLE 142 NORTH AMERICA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 143 NORTH AMERICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 144 NORTH AMERICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 145 NORTH AMERICA: ANIMAL VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                        TABLE 146 NORTH AMERICA: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 147 NORTH AMERICA: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 148 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 149 NORTH AMERICA: MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                        TABLE 150 NORTH AMERICA: ANIMAL VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
             11.3.2 US
                        11.3.2.1 US to dominate North American veterinary vaccines market
                                      FIGURE 39 US: POPULATION OF DOGS, 2012–2020 (MILLION)
                                      FIGURE 40 US: EXPENDITURE ON VET VISITS
                                      TABLE 151 HEALTHCARE EXPENDITURE ON COMPANION ANIMALS, 2018 VS. 2020
                                      FIGURE 41 INCOME OF VETERINARIANS IN US, 2017–2021
                                      FIGURE 42 NUMBER OF VETERINARIANS IN US, 2016–2020
                                      TABLE 152 US: NUMBER OF VETERINARIANS IN PRIVATE CLINICAL PRACTICES, 2014–2020
                                      TABLE 153 US: MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 154 US: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 155 US: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 156 US: MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                                      TABLE 157 US: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 158 US: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 159 US: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 160 US: MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                                      TABLE 161 US: ANIMAL VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
             11.3.3 CANADA
                        11.3.3.1 Rising pet and livestock populations to support market growth
                                      FIGURE 43 CANADA: COMPANION ANIMAL POPULATION, 2016–2020 (MILLION)
                                      TABLE 162 CANADA: VETERINARY VACCINES MARKET FORECAST, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 163 CANADA: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 164 CANADA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 165 CANADA: ANIMAL VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                                      TABLE 166 CANADA: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 167 CANADA: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 168 CANADA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 169 CANADA: MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                                      TABLE 170 CANADA: VETERINARY VACCINES MARKET ANALYSIS, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
     11.4 EUROPE 
             11.4.1 EUROPE: RECESSION IMPACT
                        TABLE 171 EUROPE: VETERINARY VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                        TABLE 172 EUROPE: MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 173 EUROPE: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 174 EUROPE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 175 EUROPE: MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                        TABLE 176 EUROPE: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 177 EUROPE: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 178 EUROPE: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 179 EUROPE: MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                        TABLE 180 EUROPE: ANIMAL VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
             11.4.2 GERMANY
                        11.4.2.1 Germany to dominate European veterinary vaccines market
                                      TABLE 181 GERMANY: MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 182 GERMANY: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 183 GERMANY: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 184 GERMANY: ANIMAL VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                                      TABLE 185 GERMANY: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 186 GERMANY: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 187 GERMANY: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 188 GERMANY: MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                                      TABLE 189 GERMANY: ANIMAL VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
             11.4.3 UK
                        11.4.3.1 Growing pet adoption to drive demand for veterinary vaccines
                                      TABLE 190 UK: VETERINARY VACCINES MARKET SIZE, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 191 UK: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 192 UK: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 193 UK: MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                                      TABLE 194 UK: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 195 UK: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 196 UK: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 197 UK: MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                                      TABLE 198 UK: VETERINARY VACCINES MARKET PREDICTION, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
             11.4.4 FRANCE
                        11.4.4.1 Rising pet ownership to support market growth
                                      TABLE 199 FRANCE: VETERINARY VACCINES MARKET RESEARCH, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 200 FRANCE: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 201 FRANCE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 202 FRANCE: ANIMAL VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                                      TABLE 203 FRANCE: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 204 FRANCE: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 205 FRANCE: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 206 FRANCE: MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                                      TABLE 207 FRANCE: ANIMAL VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
             11.4.5 ITALY
                        11.4.5.1 Increasing outbreaks of diseases to support market growth
                                      TABLE 208 ITALY: VETERINARY VACCINES MARKET FORECAST, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 209 ITALY: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 210 ITALY: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 211 ITALY: MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                                      TABLE 212 ITALY: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 213 ITALY: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 214 ITALY: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 215 ITALY: MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                                      TABLE 216 ITALY: ANIMAL VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
             11.4.6 SPAIN
                        11.4.6.1 Increase in number of veterinary practices to drive market growth
                                      TABLE 217 SPAIN: VETERINARY VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 218 SPAIN: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 219 SPAIN: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 220 SPAIN: ANIMAL VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                                      TABLE 221 SPAIN: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 222 SPAIN: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 223 SPAIN: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 224 SPAIN: MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                                      TABLE 225 SPAIN: VETERINARY VACCINES MARKET RESEARCH, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
             11.4.7 REST OF EUROPE
                        TABLE 226 REST OF EUROPE: VETERINARY VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 227 REST OF EUROPE: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 228 REST OF EUROPE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 229 REST OF EUROPE: MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                        TABLE 230 REST OF EUROPE: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 231 REST OF EUROPE: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 232 REST OF EUROPE: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 233 REST OF EUROPE: MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                        TABLE 234 REST OF EUROPE: ANIMAL VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
     11.5 LATIN AMERICA 
             11.5.1 LATIN AMERICA: RECESSION IMPACT
                        TABLE 235 LATIN AMERICA: VETERINARY VACCINES MARKET PREDICTION, BY COUNTRY, 2020–2027 (USD MILLION)
                        TABLE 236 LATIN AMERICA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 237 LATIN AMERICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 238 LATIN AMERICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 239 LATIN AMERICA: ANIMAL VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                        TABLE 240 LATIN AMERICA: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 241 LATIN AMERICA: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 242 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 243 LATIN AMERICA: MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                        TABLE 244 LATIN AMERICA: ANIMAL VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
             11.5.2 BRAZIL
                        11.5.2.1 Well-established and rapidly growing livestock industry to promote growth
                                      TABLE 245 BRAZIL: VETERINARY VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 246 BRAZIL: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 247 BRAZIL: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 248 BRAZIL: MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                                      TABLE 249 BRAZIL: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 250 BRAZIL: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 251 BRAZIL: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 252 BRAZIL: MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                                      TABLE 253 BRAZIL: VETERINARY VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
             11.5.3 MEXICO
                        11.5.3.1 Mexico to continue to be second-largest pet care market in Latin America during forecast period
                                      TABLE 254 MEXICO: VETERINARY VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 255 MEXICO: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 256 MEXICO: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 257 MEXICO: ANIMAL VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                                      TABLE 258 MEXICO: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 259 MEXICO: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 260 MEXICO: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 261 MEXICO: MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                                      TABLE 262 MEXICO: ANIMAL VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
             11.5.4 REST OF LATIN AMERICA
                        TABLE 263 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 264 REST OF LATIN AMERICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 265 REST OF LATIN AMERICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 266 REST OF LATIN AMERICA: MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                        TABLE 267 REST OF LATIN AMERICA: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 268 REST OF LATIN AMERICA: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 269 REST OF LATIN AMERICA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 270 REST OF LATIN AMERICA: MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                        TABLE 271 REST OF LATIN AMERICA: ANIMAL VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
     11.6 MIDDLE EAST & AFRICA 
             11.6.1 LOW PORK PRODUCTION AND CONSUMPTION IN MIDDLE EASTERN COUNTRIES DUE TO RELIGIOUS CUSTOMS TO LIMIT GROWTH
                        TABLE 272 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 273 MIDDLE EAST & AFRICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 274 MIDDLE EAST & AFRICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 275 MIDDLE EAST & AFRICA: ANIMAL VACCINES MARKET, BY DISEASE, 2020–2027 (USD MILLION)
                        TABLE 276 MIDDLE EAST & AFRICA: LIVESTOCK DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 277 MIDDLE EAST & AFRICA: COMPANION ANIMAL DISEASES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 278 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 279 MIDDLE EAST & AFRICA: MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                        TABLE 280 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET PREDICTION, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
 
12 COMPETITIVE LANDSCAPE (Page No. - 217)
     12.1 OVERVIEW 
     12.2 STRATEGIES ADOPTED BY KEY PLAYERS (JANUARY 2019 TO MARCH 2023) 
             FIGURE 44 KEY PLAYER STRATEGIES
     12.3 REVENUE SHARE ANALYSIS OF TOP 5 PLAYERS 
             FIGURE 45 GLOBAL VETERINARY VACCINES MARKET: REVENUE SHARE ANALYSIS OF TOP PLAYERS (2017−2021)
     12.4 MARKET SHARE ANALYSIS 
             FIGURE 46 MARKET SHARE, BY KEY PLAYER (2021)
     12.5 COMPANY FOOTPRINT 
             TABLE 281 ANIMAL VACCINES MARKET: BY TYPE
             TABLE 282 MARKET: BY DISEASE
             TABLE 283 ANIMAL VACCINES MARKET: BY TECHNOLOGY
             TABLE 284 MARKET: BY ROUTE OF ADMINISTRATION
             TABLE 285 ANIMAL VACCINES MARKET: BY DISTRIBUTION CHANNEL
     12.6 COMPANY GEOGRAPHIC FOOTPRINT 
             TABLE 286 MARKET: REGIONAL REVENUE MIX
     12.7 COMPANY EVALUATION QUADRANT 
             12.7.1 STARS
             12.7.2 EMERGING LEADERS
             12.7.3 PERVASIVE PLAYERS
             12.7.4 PARTICIPANTS
                        FIGURE 47 ANIMAL VACCINES MARKET: COMPANY EVALUATION QUADRANT (2021)
     12.8 STARTUPS/SMES EVALUATION QUADRANT 
             12.8.1 PROGRESSIVE COMPANIES
             12.8.2 DYNAMIC COMPANIES
             12.8.3 STARTING BLOCKS
             12.8.4 RESPONSIVE COMPANIES
                        FIGURE 48 ANIMAL VACCINES MARKET: EVALUATION QUADRANT FOR STARTUPS/SMES (2021)
     12.9 COMPETITIVE BENCHMARKING 
             TABLE 287 GLOBAL VETERINARY VACCINES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
     12.1 COMPETITIVE SITUATION AND TRENDS 
             12.10.1 PRODUCT LAUNCHES & APPROVALS
                        TABLE 288 PRODUCT LAUNCHES & APPROVALS
             12.10.2 DEALS
                        TABLE 289 DEALS
             12.10.3 OTHER DEVELOPMENTS
                        TABLE 290 OTHER DEVELOPMENTS
 
13 COMPANY PROFILES (Page No. - 234)
(Business overview, Products offered, Recent developments & MnM View)*
     13.1 KEY PLAYERS 
             13.1.1 ZOETIS, INC.
                        TABLE 291 ZOETIS, INC.: BUSINESS OVERVIEW
                        FIGURE 49 ZOETIS, INC.: COMPANY SNAPSHOT (2022)
             13.1.2 MERCK & CO., INC.
                        TABLE 292 MERCK & CO., INC.: BUSINESS OVERVIEW
                        FIGURE 50 MERCK & CO., INC.: COMPANY SNAPSHOT (2021)
             13.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
                        TABLE 293 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS OVERVIEW
                        FIGURE 51 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2021)
             13.1.4 ELANCO ANIMAL HEALTH
                        TABLE 294 ELANCO ANIMAL HEALTH: BUSINESS OVERVIEW
                        FIGURE 52 ELANCO ANIMAL HEALTH: COMPANY SNAPSHOT (2021)
             13.1.5 VIRBAC
                        TABLE 295 VIRBAC: BUSINESS OVERVIEW
                        FIGURE 53 VIRBAC: COMPANY SNAPSHOT (2021)
             13.1.6 CEVA SANTÉ ANIMALE
                        TABLE 296 CEVA SANTÉ ANIMALE: BUSINESS OVERVIEW
             13.1.7 PHIBRO ANIMAL HEALTH CORPORATION
                        TABLE 297 PHIBRO ANIMAL HEALTH: BUSINESS OVERVIEW
                        FIGURE 54 PHIBRO ANIMAL HEALTH: COMPANY SNAPSHOT (2021)
             13.1.8 HESTER BIOSCIENCES LIMITED
                        TABLE 298 HESTER BIOSCIENCES: BUSINESS OVERVIEW
                        FIGURE 55 HESTER BIOSCIENCES: COMPANY SNAPSHOT (2021)
             13.1.9 NEOGEN CORPORATION
                        TABLE 299 NEOGEN CORPORATION: BUSINESS OVERVIEW
                        FIGURE 56 NEOGEN CORPORATION: COMPANY SNAPSHOT (2022)
             13.1.10 HIPRA
                        TABLE 300 HIPRA: BUSINESS OVERVIEW
             13.1.11 BIOGÉNESIS BAGÓ
                        TABLE 301 BIOGÉNESIS BAGÓ: BUSINESS OVERVIEW
             13.1.12 TIANJIN RINGPU BIOTECHNOLOGY CO. LTD.
                        TABLE 302 TIANJIN RINGPU BIOTECHNOLOGY CO LTD: BUSINESS OVERVIEW
             13.1.13 CHINA ANIMAL HUSBANDRY GROUP
                        TABLE 303 CHINA ANIMAL HUSBANDRY GROUP: BUSINESS OVERVIEW
             13.1.14 JINYU BIO-TECHNOLOGY
                        TABLE 304 JINYU BIO-TECHNOLOGY: BUSINESS OVERVIEW
             13.1.15 VAXXINOVA INTERNATIONAL BV
                        TABLE 305 VAXXINOVA INTERNATIONAL BV: BUSINESS OVERVIEW
*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
     13.2 OTHER COMPANIES 
             13.2.1 ENDOVAC ANIMAL HEALTH
             13.2.2 BRILLIANT BIO PHARMA
             13.2.3 APTIMMUNE
             13.2.4 INDIAN IMMUNOLOGICALS LTD.
             13.2.5 TORIGEN PHARMACEUTICALS, INC.
             13.2.6 VEROVACCINES GMBH
             13.2.7 INTAS PHARMACEUTICALS
             13.2.8 OUROFINO ANIMAL HEALTH
             13.2.9 BIOVAC
             13.2.10 LABORATOIRE LCV
 
14 APPENDIX (Page No. - 285)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATION OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS 

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the usage of comprehensive secondary sources; directories; databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the veterinary vaccines market. It was also used to obtain important information about the key players, market classification and segmentation according to industry trends to the bottommost level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side and demand side are detailed below.

A breakdown of the primary respondents is provided below:

Breakdown of Primary Interviews: Supply-Side Participants, By Company Type, Designation, and Region

Veterinary Vaccines Market Size, and Share

Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.

Note 2: Other primaries include sales managers, marketing managers, and product managers.

Note 3: Companies are classified into tiers based on their total revenue. As of 2020: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Breakdown of Primary Interviews: Demand-Side Participants, By End User, Designation, and Region

Veterinary Vaccines Market Size, and Share

Note: Others include department heads, research scientists, and professors.

Market Size Estimation

The total size of the veterinary vaccines market was arrived at after data triangulation from two different approaches, as mentioned below. After each approach, the weighted average of all approaches was taken based on the level of assumptions used in each approach.

Data Triangulation

After arriving at the market size, the total market was divided into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics for all segments and sub-segments, data triangulation and market breakdown procedures were employed, wherever applicable. The following figure shows the market validation, source structure, and data triangulation methodology implemented in this report’s market engineering process.

Market Definition

A veterinary vaccine is a biological preparation that provides immunity for a particular animal disease. Vaccination aids in improving the health of animals, reducing the spread of zoonotic diseases, and increasing the production of milk, meat, eggs, wool, and other related products.

Key Stakeholders

  • Animal vaccine manufacturers
  • Animal healthcare product manufacturers
  • Animal vaccine distributors and wholesalers
  • Animal welfare associations
  • Veterinary clinics and care centers
  • Research and consulting firms
  • Research institutes
  • Contract research organizations
  • Contract manufacturing organizations
  • Venture capitalists

Objectives of the Study

  • To define, describe, and forecast the veterinary vaccines market based on type, disease, technology, route of distribution, distribution channel, and region
  • To provide detailed information regarding the drivers, restraints, opportunities, and challenges influencing the growth of the veterinary vaccines market
  • To strategically analyze the ecosystem, regulations, patenting trend, value chain, supply chain, Porter’s five forces, technologies, key stakeholders and buying criteria, and prices pertaining to the market under study
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To profile key players and comprehensively analyze their market shares and core competencies
  • To track and analyze competitive developments such as partnerships, agreements, and joint ventures; mergers and acquisitions; new product developments; and R&D activities in the veterinary vaccines market

Available customizations

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)

Geographic Analysis

  • Further breakdown of the RoE veterinary vaccines market into Austria, Finland, and others
  • <
  • Further breakdown of the RoLATAM veterinary vaccines market into Argentina, Colombia, Chile, and others

Competitive Landscape Assessment

  • Market share analysis for the North America and Europe region, which provides market shares of the top 3–5 key players in the veterinary vaccines market
  • Competitive leadership mapping for established players in the US
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
PH 3475
Published ON
Apr, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Veterinary Vaccines Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback